Overview

The study participant is being asked to be in a research study called LEGACY, because you were treated for high-risk neuroblastoma (HR-NBL).

Primary Objective

To determine the feasibility of conducting comprehensive evaluations, leveraging the established SJLIFE (St. Jude Lifetime Cohort Study) study infrastructure, in survivors of HR-NBL (high-risk neuroblastoma) who are greater than 2 years from completion of contemporary therapy and were previously treated at SJCRH (St. Jude Children's Research Hospital).

Exploratory Objectives

• To describe the health outcomes of survivors of HR-NBL previously treated at SJCRH with contemporary era therapy who are greater than 2 years from completion of therapy.
• To describe the relationship between patient outcomes and social determinants of health (SDOH) in survivors of HR-NBL previously treated at SJCRH with contemporary era therapy who are greater than 2 years from completion of therapy.

Eligibility

Inclusion Criteria:

• Participants were diagnosed with neuroblastoma at < 18 years of age and categorized as high-risk at that time, according to INSS26 or INRGSS27 criteria.
• Participants were treated for HR-NBL at SJCRH on NB2012 or as per NB2012.
• Participants are ≥ 2 years from completion of therapy. Participants are 5 years of age or older.
• Participant or legal guardian is able and willing to give informed consent.
• Participants may choose to participate in all or a fraction of the proposed assessments; refusal to participate in some aspects of the study will not preclude their inclusion.
• Participants must also complete enrollment on SJLIFE.

Exclusion Criteria:

• Inability or unwillingness of research participant or legal guardian/representative to give written informed consent.
• Participants who had relapsed or refractory disease during or following completion of modern era treatment for HR-NBL.
• Participants who are pregnant or breastfeeding.
• Participants who are unable to read and understand English